Research Paper Volume 14, Issue 10 pp 4471—4485

NcRNAs-mediated P2RX1 expression correlates with clinical outcomes and immune infiltration in patients with breast invasive carcinoma

Yiyue Xu1,2,3,4,5,6, , Bing Zou6, , Bingjie Fan6, , Butuo Li6, , Jinming Yu6, , Linlin Wang6, &, , Jin Zhang1,2,3,4,5, ,

  • 1 3rd Department of Breast Cancer, China Tianjin Breast Cancer Prevention, Treatment and Research Center, Tianjin Medical University Cancer Institute and Hospital, Tianjin, P.R. China
  • 2 Key Laboratory of Breast Cancer Prevention and Therapy of Ministry of Education, Tianjin, P.R. China
  • 3 Key Laboratory of Cancer Prevention and Therapy, Tianjin, P.R. China
  • 4 Tianjin’s Clinical Research Center for Cancer, Tianjin, P.R. China
  • 5 Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, P.R. China
  • 6 Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, P.R. China

Received: February 6, 2022       Accepted: May 7, 2022       Published: May 18, 2022
How to Cite

Copyright: © 2022 Xu et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


The development of novel treatments for breast invasive carcinoma (BC) has been stagnant. P2RX1, a member of the purinergic receptor family, has been found to have a prognostic impact in several tumors. Therefore, we analyzed the expression pattern of P2RX1 in pan-cancers including BC and its impact on survival and found that the expression level of P2RX1 was lower in BC compared with para-cancerous tissues, and higher P2RX1 expression indicated better prognoses. But real-time quantitative reverse transcription PCR (RT-qPCR) and Western blot detected that the P2RX1 expression in normal mammary epithelial cells was lower than that in tumor cells. Then we comprehensively analyzed the regulatory mechanism and protein-protein interaction network, and found that P2RX1 was significantly positively linked with immune cell infiltration and immune checkpoints.


BC: breast invasive carcinoma; TME: tumor microenvironment; TILs: tumor-infiltrating lymphocytes; ATP: adenosine triphosphate; ncRNAs: non-coding RNAs; miRNAs: microRNAs; lncRNAs: long non-coding RNAs; BLCA: bladder urothelial carcinoma; CESC: cervical squamous cell carcinoma and endocervical adenocarcinoma; COAD: colon adenocarcinoma; ESCA: esophageal carcinoma; KICH: kidney chromophobe; LUAD: lung adenocarcinoma; LUSC: lung squamous cell carcinoma; PRAD: prostate adenocarcinoma; READ: rectum adenocarcinoma; STAD: stomach adenocarcinoma; UCEC: uterine corpus endometrial carcinoma; HNSC: head and neck squamous cell carcinoma; KIRC: kidney renal clear cell carcinoma; TCGA: the Cancer Genome Atlas; GTEx: the Genotype-Tissue Expression; GEPIA: the Gene Expression Profiling Interactive Analysis; OS: overall survival; DFS: disease-free survival; PPI: protein-protein interaction; RT-qPCR: real-time quantitative reverse transcription PCR.